Expert opinion of the European Tuberculosis Laboratory Initiative core group members for the WHO European Region.
This guideline is intended to provide requirements to applicants wishing to submit
applications for registration of medicines in Botswana.
Автоматизированная технология амплификации нуклеиновых кислот в режиме реального времени для быстрого и одновременного выявления туберкулеза и устойчивости к р...ифампицину: система Xpert MTB/RIF.
Программное заявление.
more
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more
CBR Advisory Working Group | Co-ordinator: Karen Heinicke-Motsch
Evidence from Low and Middle Income Countries